V. Georgoulias

发表

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study

N. Maniadakis, G. Kourlaba, G. Koumakis, 2015, BMC Health Services Research.

Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece

N. Maniadakis, A. Pallis, V. Fragoulakis, 2007, Current medical research and opinion.

Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.

N. Maniadakis, A. Pallis, V. Fragoulakis, 2007, Lung cancer.

Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

N. Maniadakis, A. Pallis, V. Fragoulakis, 2012, Lung Cancer.

Illness perceptions in Greek patients with cancer: a validation of the Revised‐Illness Perception Questionnaire

Z. Giannousi, G. Samonis, I. Manaras, 2010, Psycho-oncology.

1222OA RANDOMIZED, OPEN-LABEL, PHASE III TRIAL OF AFATINIB (A) VS ERLOTINIB (E) AS SECOND-LINE TREATMENT OF PATIENTS (PTS) WITH ADVANCED SQUAMOUS CELL CARCINOMA (SCC) OF THE LUNG FOLLOWING FIRST-LINE PLATINUM-BASED CHEMOTHERAPY: LUX-LUNG 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced Breast Cancer: Treatment with Docetaxel/Epirubicin

A. Pallis, V. Georgoulias, V. Mavroudis, 2008 .

Spatio-Temporal Variation of Lung Cancer in Crete, 1992–2013. Economic or Health Crisis?

N. Tzanakis, C. Lionis, D. Sifaki-Pistolla, 2022, International journal of environmental research and public health.

Evidence-Based Conceptual Collection of Methods for Spatial Epidemiology and Analysis to Enhance Cancer Surveillance and Public Health

N. Tzanakis, G. Nikiforidis, C. Lionis, 2022, International journal of environmental research and public health.

Nuclear localization of human AP endonuclease 1 (HAP1/Ref‐1) associates with prognosis in early operable non‐small cell lung cancer (NSCLC)

A. Harris, K. Gatter, I. Hickson, 1999, The Journal of pathology.

Deep Learning and Association Rule Mining for Predicting Drug Response in Cancer. A Personalised Medicine Approach

Konstantinos Vougas, Vassilis G. Gorgoulis, Jiri Bartek, 2016, bioRxiv.

Skin and Soft Tissue Infections in Patients with Solid Tumours

A. Valachis, F. Economidou, G. Samonis, 2012, TheScientificWorldJournal.

Identification of the M541L sequence variation of the transmembrane KIT domain in Merkel cell carcinoma.

Nektarios Tavernarakis, Jean Kanitakis, A. Tosca, 2011, Anticancer research.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

E. Felip, A. Ardizzoni, Y. Min, 2021, EClinicalMedicine.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial

K. Syrigos, E. Felip, J. Soria, 2018, JAMA oncology.

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

A. Børresen-Dale, P. Sætrom, B. Nielsen, 2016, Journal of Translational Medicine.

Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining.

Aristotelis Tsirigos, Hua Zhou, Konstantinos Vougas, 2019, Pharmacology & therapeutics.

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.

K. Syrigos, E. Felip, J. Soria, 2015, The Lancet. Oncology.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

K. Syrigos, E. Felip, J. Soria, 2017, Lung cancer.

Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).

K. Syrigos, E. Felip, J. Soria, 2015 .

Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway

D. Iliopoulos, G. Poultsides, C. Polytarchou, 2015, BMC Cancer.

First‐line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

G. Chalkiadakis, G. Samonis, J. Souglakos, 1998, Cancer.

Lung cancer and tobacco smoking in Crete, Greece: reflections from a population-based cancer registry from 1992 to 2013

P. Kyriakidis, N. Tzanakis, C. Lionis, 2017, Tobacco induced diseases.

Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.

K. Syrigos, G. Mountzios, D. Mavroudis, 2022, Future oncology.

MKAD-21 Suppresses the Oncogenic Activity of the miR-21/PPP2R2A/ERK Molecular Network in Bladder Cancer

D. Iliopoulos, A. Pantuck, D. Slamon, 2018, Molecular Cancer Therapeutics.

P3.01-043 Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung

E. Felip, J. Soria, A. Ardizzoni, 2017 .

OA23.03 Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial

E. Felip, J. Soria, A. Ardizzoni, 2017 .

Excerpts from the 1st international NTNU symposium on current and future clinical biomarkers of cancer: innovation and implementation, June 16th and 17th 2016, Trondheim, Norway

A. Børresen-Dale, P. Sætrom, B. Nielsen, 2016, Journal of Translational Medicine.

Lung cancer and annual mean exposure to outdoor air pollution in Crete, Greece

N. Tzanakis, C. Lionis, D. Sifaki-Pistolla, 2017, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.

N. Maniadakis, A. Pallis, V. Fragoulakis, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Incidence of breast cancer on Crete, 1994-1995.

I. Vlachonikolis, V. Georgoulias, T. J. Aletra, 2002, European journal of cancer.

Expression of p53, p21/waf, bcl-2, bax, Rb and Ki67 proteins in colorectal adenocarcinomas

M. Tzardi, M. Vlychou, V. Gorgoulis, 1999, Medical oncology.

Mortality from malignant neoplasms in Crete, 1992-1993.

I G Vlachonikolis, I. Vlachonikolis, A E Philalithis, 1998, Journal of epidemiology and community health.

Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders

K. Syrigos, E. Felip, J. Soria, 2017 .

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Third CECOG consensus on the systemic treatment of non-small-cell lung cancer.

C. Gridelli, R. Pirker, T. Ciuleanu, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.